Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
07/21 SANOFI : Annual fundraiser honors nonprofits
07/21 SANOFI : Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupil..
07/21 SANOFI : and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) t..
07/20 SANOFI : Disclosure of trading in own shares
07/20 AUROBINDO PHARMA : Gets nod to sell kidney drug
07/20 SANOFI : 2017-2018 Flu Vaccine on Its Way to US
07/19 SANOFI : Pasteur ships first vaccine doses ahead of flu season
07/19 SANOFI : Emergent to buy Sanofi smallpox vaccine and take on CDC contract
07/19 SANOFI : FRAMINGHAM Traffic, city transition may snarl hotel project
07/18 SANOFI : begins shipments of 2017-2018 flu vaccines
More news
News from SeekingAlpha
07/21 Sirukumab's Panel And U.S. Decision For Medicines Company
07/21 European advisory group backs approval of 11 new meds
07/20 FDA tentatively OKs Merck's biologic basal insulin
07/20 Ablynx and Sanofi team up to develop Nanobody-based therapeutics for inflamma..
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
Financials (€)
Sales 2017 36 571 M
EBIT 2017 9 546 M
Net income 2017 7 948 M
Debt 2017 4 763 M
Yield 2017 3,74%
P/E ratio 2017 12,97
P/E ratio 2018 16,81
EV / Sales 2017 2,94x
EV / Sales 2018 2,82x
Capitalization 102 777 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,1 €
Spread / Average Target 5,7%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.01%119 827
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.5.46%221 492
NOVARTIS9.72%220 936
PFIZER3.08%199 378